Xeris Biopharma Holdings (LTS:0A8E) Accounts Payable : $2.3 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Accounts Payable?

Xeris Biopharma Holdings's Accounts Payable for the quarter that ended in Dec. 2024 was $2.3 Mil.

Xeris Biopharma Holdings's quarterly Accounts Payable increased from Jun. 2024 ($5.8 Mil) to Sep. 2024 ($7.5 Mil) but then declined from Sep. 2024 ($7.5 Mil) to Dec. 2024 ($2.3 Mil).

Xeris Biopharma Holdings's annual Accounts Payable increased from Dec. 2022 ($4.6 Mil) to Dec. 2023 ($11.6 Mil) but then declined from Dec. 2023 ($11.6 Mil) to Dec. 2024 ($2.3 Mil).

Xeris Biopharma Holdings Accounts Payable Historical Data

The historical data trend for Xeris Biopharma Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Accounts Payable Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

3.12

8.92

4.61

11.57

2.29

Xeris Biopharma Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable	Get a 7-Day Free Trial															11.57	7.09	5.80	7.45	2.29

Xeris Biopharma Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Xeris Biopharma Holdings Accounts Payable Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines